Basic Information
| LncRNA/CircRNA Name | LINC00152 |
| Synonyms | CYTOR, C2orf59, LINC00152, NCRNA00152 |
| Region | GRCh38_2:87454781-87636740 |
| Ensemble | ENSG00000222041 |
| Refseq | NR_024204 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | glioblastoma |
| ICD-0-3 | NA |
| Methods | qPCR, Western blot, luciferase reporter assay |
| Sample | glioblastoma tissues, cell lines (LN229, U87-MG) |
| Expression Pattern | |
| Function Description | LINC00152 was closely associated with glioma WHO classification and poor prognosis, and indicated a poor prognosis in glioblastoma patients. LINC00152 modulated GBM malignant progression and proneural-mesenchymal transition through the miR-612 dependent AKT2/NF-?B pathway. |
| Pubmed ID | 30043319 |
| Year | 2018 |
| Title | Blocking LINC00152 Suppresses Glioblastoma Malignancy by Impairing Mesenchymal Phenotype Through the miR-612/AKT2/NF-?B Pathway. |
External Links
| Links for LINC00152 | GenBank HGNC NONCODE |
| Links for glioblastoma | OMIM COSMIC |